HAPO Trial and Gestational Diabetes Management
Screening Timing and Criteria
Screen all pregnant women at 24-28 weeks of gestation using either a one-step or two-step approach, based on the HAPO study findings that demonstrated continuous graded relationships between maternal glycemia and adverse outcomes without clear thresholds. 1, 2, 3
One-Step Strategy (IADPSG Criteria - Preferred)
Perform a 75-g oral glucose tolerance test (OGTT) at 24-28 weeks after an overnight fast of at least 8 hours. Diagnose GDM if ANY single value meets or exceeds:
- Fasting: ≥92 mg/dL (5.1 mmol/L)
- 1-hour: ≥180 mg/dL (10.0 mmol/L)
- 2-hour: ≥153 mg/dL (8.5 mmol/L)
These thresholds were derived directly from the HAPO study, representing glucose levels at which odds for adverse outcomes (macrosomia, cesarean delivery, neonatal hypoglycemia, cord C-peptide >90th percentile) reached 1.75 times the mean values 1, 3, 4.
Two-Step Strategy (Alternative)
Step 1: 50-g glucose load test (GLT) at 24-28 weeks (non-fasting). If ≥130,135, or 140 mg/dL at 1 hour, proceed to Step 2.
Step 2: 100-g OGTT (fasting). Diagnose GDM if at least TWO values meet or exceed (Carpenter-Coustan criteria):
- Fasting: 95 mg/dL (5.3 mmol/L)
- 1-hour: 180 mg/dL (10.0 mmol/L)
- 2-hour: 155 mg/dL (8.6 mmol/L)
- 3-hour: 140 mg/dL (7.8 mmol/L) 2, 3
Early Screening Considerations
**Screen high-risk women at first prenatal visit (<15 weeks) for pre-existing diabetes using standard non-pregnancy criteria** (fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL, or A1C ≥6.5%). Risk factors include: prior GDM, obesity (BMI ≥30), age >35, strong family history, high-risk ethnicity, or prior macrosomic infant 2.
For early abnormal glucose metabolism (fasting 110-125 mg/dL or A1C 5.9-6.4%), provide nutrition counseling and weekly glucose monitoring, as these women face higher risks of adverse outcomes and later GDM diagnosis 2, 3.
First-Line Management
Immediate Interventions
All women diagnosed with GDM should receive:
- Nutritional counseling - This is the cornerstone of therapy 5
- Blood glucose self-monitoring with targets:
- Fasting: <95 mg/dL
- 1-hour postprandial: <140 mg/dL 5
- Moderate-intensity physical activity unless contraindicated 5
Pharmacologic Therapy
Initiate insulin therapy if glucose targets cannot be maintained with lifestyle modifications alone - this occurs in approximately 20% of cases 6, 5. Insulin is the first-choice pharmacologic agent (Evidence level A) 5.
Critical Context from HAPO
The HAPO study fundamentally changed GDM diagnosis by demonstrating that adverse outcomes (macrosomia, cesarean delivery, neonatal hypoglycemia, hyperinsulinemia) increase continuously with maternal glucose levels, with no clear threshold 1, 6, 4. This multinational study of >23,000 pregnant women showed that even glucose levels previously considered "normal" carried increased risk 1, 7.
Important Caveats
- The one-step approach identifies approximately 15-20% of pregnancies as GDM (versus 5-6% with older criteria), but 80-90% can be managed with lifestyle alone 1, 6
- Both screening strategies are acceptable; choice depends on local resources and practice patterns 1, 2
- Do NOT use OGTT criteria for early pregnancy screening (<24 weeks) - they were not validated in this population 2
- After bariatric surgery, avoid OGTT due to hypoglycemia risk 5
Postpartum Follow-up
Test all women with GDM at 4-12 weeks postpartum using 75-g OGTT with non-pregnancy criteria, then screen for diabetes/prediabetes at least every 3 years lifelong 1. Women with prediabetes should receive intensive lifestyle interventions or metformin 1.